2023

Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting in Vancouver, BC, Canada. The company and scientific collaborators will collectively present ten studies and host three corporate workshops, showcasing their latest advancements in Next-Generation Sequencing (NGS) technology and oncology […]

Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association (AMA) for their FDA approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal™ CDx is a NGS

Enables content for newly launched Illumina MiSeq™ i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels Natick, MA – October 16, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has today announced an expansion of their existing partnership with Illumina, through which a broader portfolio of Pillar’s oncoReveal™ NGS panels will now be

Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions. Natick, MA – September 10, 2024 – Pillar Biosciences, Inc., has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling

Natick, MA – August 27, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy. A team at New York’s Memorial Sloan

Natick, MA – July 30, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the first national molecular reference laboratory to verify and launch oncoReveal™ CDx. The oncoReveal™ CDx pan-cancer solid tumor IVD kit has been FDA PMA approved for general tumor profiling for 22 clinically

Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April 23, 2024 Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today

Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will be presenting at the NYBIO | NYSE Life Science Company Showcase on December 14th. This event, organized by NewYorkBIO in partnership with the New York Stock Exchange (NYSE), brings

NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth

Assays Focus on Accelerating Cancer Research INDIANAPOLIS – November 6, 2023 – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with next-generation sequencing (NGS) research solutions. Today the company announces a collaboration agreement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing solutions